{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:14:41Z","timestamp":1783487681323,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2254, HEIST"],"award-info":[{"award-number":["GRK 2254, HEIST"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["PREDICT-PACA, 70113834"],"award-info":[{"award-number":["PREDICT-PACA, 70113834"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["TRANSCAN VI\u2014PMTR-PanNET, ID 640 01KT1901B"],"award-info":[{"award-number":["TRANSCAN VI\u2014PMTR-PanNET, ID 640 01KT1901B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young researcher grant of the Graduate & Professional Training Center Ulm"},{"name":"German Federal Minister of Education and Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic neuroendocrine tumors (PanNETs) are a rare tumor entity with largely unpredictable progression and increasing incidence in developed countries. Molecular pathways involved in PanNETs development are still not elucidated, and specific biomarkers are missing. Moreover, the heterogeneity of PanNETs makes their treatment challenging and most approved targeted therapeutic options for PanNETs lack objective responses. Here, we applied a systems biology approach integrating dynamic modeling strategies, foreign classifier tailored approaches, and patient expression profiles to predict PanNETs progression as well as resistance mechanisms to clinically approved treatments such as the mammalian target of rapamycin complex 1 (mTORC1) inhibitors. We set up a model able to represent frequently reported PanNETs drivers in patient cohorts, such as Menin-1 (MEN1), Death domain associated protein (DAXX), Tuberous Sclerosis (TSC), as well as wild-type tumors. Model-based simulations suggested drivers of cancer progression as both first and second hits after MEN1 loss. In addition, we could predict the benefit of mTORC1 inhibitors on differentially mutated cohorts and hypothesize resistance mechanisms. Our approach sheds light on a more personalized prediction and treatment of PanNET mutant phenotypes.<\/jats:p>","DOI":"10.1038\/s41540-023-00283-8","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T14:01:44Z","timestamp":1685800904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-0269","authenticated-orcid":false,"given":"Silke D.","family":"Werle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-5832","authenticated-orcid":false,"given":"Nensi","family":"Ikonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Lausser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika M. T. U.","family":"Kestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-0509","authenticated-orcid":false,"given":"Felix M.","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Gress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika M. R.","family":"Kestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4759-5254","authenticated-orcid":false,"given":"Hans A.","family":"Kestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"key":"283_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/apc.2019.06.02","volume":"2","author":"JL Buicko","year":"2019","unstructured":"Buicko, J. L. et al. Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. Ann. Pancreat. Cancer 2, 12 (2019).","journal-title":"Ann. Pancreat. Cancer"},{"key":"283_CR2","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1158\/1078-0432.CCR-16-0435","volume":"22","author":"JE Maxwell","year":"2016","unstructured":"Maxwell, J. E., Sherman, S. K. & Howe, J. R. Translational diagnostics and therapeutics in pancreatic neuroendocrine tumors. Clin. Cancer Res. 22, 5022\u20135029 (2016).","journal-title":"Clin. Cancer Res."},{"key":"283_CR3","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3748\/wjg.v26.i28.4036","volume":"26","author":"GB Mpilla","year":"2020","unstructured":"Mpilla, G. B., Philip, P. A., El-Rayes, B. & Azmi, A. S. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World J. Gastroenterol. 26, 4036\u20134054 (2020).","journal-title":"World J. Gastroenterol."},{"key":"283_CR4","unstructured":"Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. WHO Classification Of Tumours Of The Digestive System (World Health Organization, 2010)."},{"key":"283_CR5","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/0008-5472.CAN-19-2232","volume":"80","author":"Y Yamauchi","year":"2020","unstructured":"Yamauchi, Y. et al. Rb and p53 execute distinct roles in the development of pancreatic neuroendocrine tumors. Cancer Res. 80, 3620\u20133630 (2020).","journal-title":"Cancer Res."},{"key":"283_CR6","unstructured":"Osamura, R. Y. et al. WHO Classification Of Tumours Of Endocrine Organs (IARC, Lyon, 2017)."},{"key":"283_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/07435800.2010.525085","volume":"36","author":"E Batcher","year":"2011","unstructured":"Batcher, E., Madaj, P. & Gianoukakis, A. G. Pancreatic neuroendocrine tumors. Endocr. Res. 36, 35\u201343 (2011).","journal-title":"Endocr. Res."},{"key":"283_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.5732\/cjc.012.10295","volume":"32","author":"C Ro","year":"2013","unstructured":"Ro, C., Chai, W., Yu, V. E. & Yu, R. Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment. Chin. J. Cancer 32, 312\u2013324 (2013).","journal-title":"Chin. J. Cancer"},{"key":"283_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jso.22118","volume":"105","author":"CL Roland","year":"2012","unstructured":"Roland, C. L. et al. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J. Surg. Oncol. 105, 595\u2013600 (2012).","journal-title":"J. Surg. Oncol."},{"key":"283_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi, M. et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103, 153\u2013171 (2016).","journal-title":"Neuroendocrinology"},{"key":"283_CR11","doi-asserted-by":"publisher","first-page":"562505","DOI":"10.3389\/fendo.2020.562505","volume":"11","author":"S Zanini","year":"2020","unstructured":"Zanini, S., Renzi, S., Giovinazzo, F. & Bermano, G. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Front. Endocrinol. 11, 562505 (2020).","journal-title":"Front. Endocrinol."},{"key":"283_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11864-014-0294-4","volume":"15","author":"J Chan","year":"2014","unstructured":"Chan, J. & Kulke, M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr. Treat. Options Oncol. 15, 365\u2013379 (2014).","journal-title":"Curr. Treat. Options Oncol."},{"key":"283_CR13","doi-asserted-by":"publisher","first-page":"djv123","DOI":"10.1093\/jnci\/djv123","volume":"107","author":"RA Fran\u00e7ois","year":"2015","unstructured":"Fran\u00e7ois, R. A. et al. Targeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumors. J. Natl Cancer Inst. 107, djv123 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"283_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/14737140.2018.1496822","volume":"18","author":"L Lee","year":"2018","unstructured":"Lee, L., Ito, T. & Jensen, R. T. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev. Anticancer Ther. 18, 837\u2013860 (2018).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"283_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0022-5193(69)90015-0","volume":"22","author":"SA Kauffman","year":"1969","unstructured":"Kauffman, S. A. Metabolic stability and epigenesis in randomly constructed genetic nets. J. Theor. Biol. 22, 437\u2013467 (1969).","journal-title":"J. Theor. Biol."},{"key":"283_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.csbj.2020.03.001","volume":"18","author":"JD Schwab","year":"2020","unstructured":"Schwab, J. D., K\u00fchlwein, S. D., Ikonomi, N., K\u00fchl, M. & Kestler, H. A. Concepts in Boolean network modeling: What do they all mean. Comput. Struct. Biotechnol. J. 18, 571\u2013582 (2020).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"283_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3389\/fphys.2020.00848","volume":"11","author":"N Ikonomi","year":"2020","unstructured":"Ikonomi, N., K\u00fchlwein, S. D., Schwab, J. D. & Kestler, H. A. Awakening the HSC: dynamic modeling of hsc maintenance unravels regulation of the TP53 pathway and quiescence. Front. Physiol. 11, 848 (2020).","journal-title":"Front. Physiol."},{"key":"283_CR18","doi-asserted-by":"publisher","first-page":"e1005741","DOI":"10.1371\/journal.pcbi.1005741","volume":"13","author":"P Meyer","year":"2017","unstructured":"Meyer, P. et al. A model of the onset of the senescence associated secretory phenotype after DNA damage induced senescence. PLoS Comput. Biol. 13, e1005741 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"283_CR19","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1016\/j.csbj.2021.09.012","volume":"19","author":"JD Schwab","year":"2021","unstructured":"Schwab, J. D. et al. Reconstructing Boolean network ensembles from single-cell data for unraveling dynamics in the aging of human hematopoietic stem cells. Comput. Struct. Biotechnol. J. 19, 5321\u20135332 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"283_CR20","doi-asserted-by":"publisher","first-page":"e0195126","DOI":"10.1371\/journal.pone.0195126","volume":"13","author":"L Siegle","year":"2018","unstructured":"Siegle, L. et al. A Boolean network of the crosstalk between IGF and Wnt signaling in aging satellite cells. PLoS ONE 13, e0195126 (2018).","journal-title":"PLoS ONE"},{"key":"283_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/cancers13040725","volume":"13","author":"SD Werle","year":"2021","unstructured":"Werle, S. D. et al. Unraveling the molecular tumor-promoting regulation of Cofilin-1 in pancreatic cancer. Cancers 13, 725 (2021).","journal-title":"Cancers"},{"key":"283_CR22","doi-asserted-by":"publisher","first-page":"E691","DOI":"10.3390\/cancers12030691","volume":"12","author":"KB Luley","year":"2020","unstructured":"Luley, K. B. et al. A comprehensive molecular characterization of the pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. Cancers 12, E691 (2020).","journal-title":"Cancers"},{"key":"283_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1399-0004.2011.01805.x","volume":"82","author":"AM Larson","year":"2012","unstructured":"Larson, A. M. et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin. Genet. 82, 558\u2013563 (2012).","journal-title":"Clin. Genet."},{"key":"283_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1677\/ERC-10-0028","volume":"17","author":"V Corbo","year":"2010","unstructured":"Corbo, V. et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr. Relat. Cancer 17, 771\u2013783 (2010).","journal-title":"Endocr. Relat. Cancer"},{"key":"283_CR25","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/2159-8290.CD-15-0068","volume":"5","author":"A Sadanandam","year":"2015","unstructured":"Sadanandam, A. et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov. 5, 1296\u20131313 (2015).","journal-title":"Cancer Discov."},{"key":"283_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djt135","volume":"105","author":"J Zhang","year":"2013","unstructured":"Zhang, J. et al. Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J. Natl Cancer Inst. 105, 1005\u20131017 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"283_CR27","first-page":"5063","volume":"30","author":"M Ghayouri","year":"2010","unstructured":"Ghayouri, M. et al. Activation of the serine\/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res. 30, 5063\u20135067 (2010).","journal-title":"Anticancer Res."},{"key":"283_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1677\/joe.0.1790073","volume":"179","author":"SS Guo","year":"2003","unstructured":"Guo, S. S. et al. Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J. Endocrinol. 179, 73\u201379 (2003).","journal-title":"J. Endocrinol."},{"key":"283_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1572-0241.2006.00367.x","volume":"101","author":"L Thomas-Marques","year":"2006","unstructured":"Thomas-Marques, L. et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am. J. Gastroenterol. 101, 266\u2013273 (2006).","journal-title":"Am. J. Gastroenterol."},{"key":"283_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/ijms19030747","volume":"19","author":"G Lamberti","year":"2018","unstructured":"Lamberti, G. et al. The role of mTOR in neuroendocrine tumors: future cornerstone of a winning strategy. Int J. Mol. Sci. 19, 747 (2018).","journal-title":"Int J. Mol. Sci."},{"key":"283_CR31","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00280-009-1094-6","volume":"65","author":"T Shida","year":"2010","unstructured":"Shida, T. et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother. Pharmacol. 65, 889\u2013893 (2010).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"283_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao, Y. et al. DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199\u20131203 (2011).","journal-title":"Science"},{"key":"283_CR33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/jhbp.210","volume":"22","author":"G Capurso","year":"2015","unstructured":"Capurso, G., Archibugi, L. & Delle Fave, G. Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors. J. Hepatobiliary Pancreat. Sci. 22, 594\u2013601 (2015).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"283_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","volume":"130","author":"MR Junttila","year":"2007","unstructured":"Junttila, M. R. et al. CIP2A inhibits PP2A in human malignancies. Cell 130, 51\u201362 (2007).","journal-title":"Cell"},{"key":"283_CR35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1677\/ERC-07-0108","volume":"14","author":"V Fendrich","year":"2007","unstructured":"Fendrich, V. et al. Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum. Endocr. Relat. Cancer 14, 865\u2013874 (2007).","journal-title":"Endocr. Relat. Cancer"},{"key":"283_CR36","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1158\/1078-0432.CCR-11-3264","volume":"18","author":"LH Tang","year":"2012","unstructured":"Tang, L. H. et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4\/cdk6. Clin. Cancer Res. 18, 4612\u20134620 (2012).","journal-title":"Clin. Cancer Res."},{"key":"283_CR37","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","volume":"19","author":"L Lee","year":"2018","unstructured":"Lee, L., Ito, T. & Jensen, R. T. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin. Pharmacother. 19, 909\u2013928 (2018).","journal-title":"Expert Opin. Pharmacother."},{"key":"283_CR38","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1158\/1535-7163.MCT-17-0058","volume":"16","author":"MA Orr-Asman","year":"2017","unstructured":"Orr-Asman, M. A. et al. mTOR kinase inhibition effectively decreases progression of a subset of neuroendocrine tumors that progress on rapalog therapy and delays cardiac impairment. Mol. Cancer Ther. 16, 2432\u20132441 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"283_CR39","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1210\/jc.2003-031228","volume":"89","author":"P St\u00e5lberg","year":"2004","unstructured":"St\u00e5lberg, P. et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1\/preadipocyte factor-1, proliferating cell nuclear antigen, and QM\/Jif-1. J. Clin. Endocrinol. Metab. 89, 2326\u20132337 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"283_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/315115a0","volume":"315","author":"D Hanahan","year":"1985","unstructured":"Hanahan, D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin\/simian virus 40 oncogenes. Nature 315, 115\u2013122 (1985).","journal-title":"Nature"},{"key":"283_CR41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev.ge.22.120188.002403","volume":"22","author":"D Hanahan","year":"1988","unstructured":"Hanahan, D. Dissecting multistep tumorigenesis in transgenic mice. Annu. Rev. Genet. 22, 479\u2013519 (1988).","journal-title":"Annu. Rev. Genet."},{"key":"283_CR42","doi-asserted-by":"publisher","first-page":"160872","DOI":"10.1098\/rsos.160872","volume":"4","author":"AI Lavrova","year":"2017","unstructured":"Lavrova, A. I., Postnikov, E. B., Zyubin, A. Y. & Babak, S. V. Ordinary differential equations and Boolean networks in application to modelling of 6-mercaptopurine metabolism. R. Soc. Open Sci. 4, 160872 (2017).","journal-title":"R. Soc. Open Sci."},{"key":"283_CR43","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1089\/cmb.2011.0031","volume":"18","author":"A Veliz-Cuba","year":"2011","unstructured":"Veliz-Cuba, A. & Stigler, B. Boolean models can explain bistability in the lac operon. J. Comput Biol. 18, 783\u2013794 (2011).","journal-title":"J. Comput Biol."},{"key":"283_CR44","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fphys.2017.00645","volume":"8","author":"M Cantone","year":"2017","unstructured":"Cantone, M., Santos, G., Wentker, P., Lai, X. & Vera, J. Multiplicity of mathematical modeling strategies to search for molecular and cellular insights into bacteria lung infection. Front Physiol. 8, 645 (2017).","journal-title":"Front Physiol."},{"key":"283_CR45","doi-asserted-by":"crossref","unstructured":"Laschov, D., Margaliot, M. & Even, G. Observability of Boolean networks is NP-hard. 2012 IEEE 27th Convention of Electrical and Electronics Engineers in Israel, p. 1\u20135 (IEEE, 2012).","DOI":"10.1109\/EEEI.2012.6377137"},{"key":"283_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-016-0341-9","volume":"10","author":"SH Cho","year":"2016","unstructured":"Cho, S. H., Park, S. M., Lee, H. S., Lee, H. Y. & Cho, K. H. Attractor landscape analysis of colorectal tumorigenesis and its reversion. BMC Syst. Biol. 10, 96 (2016).","journal-title":"BMC Syst. Biol."},{"key":"283_CR47","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s12022-008-9044-0","volume":"19","author":"M Jamali","year":"2008","unstructured":"Jamali, M. & Chetty, R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr. Pathol. 19, 282\u2013288 (2008).","journal-title":"Endocr. Pathol."},{"key":"283_CR48","doi-asserted-by":"publisher","first-page":"691557","DOI":"10.3389\/fendo.2021.691557","volume":"12","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Prognostic significance of altered ATRX\/DAXX gene in pancreatic neuroendocrine tumors: a meta-analysis. Front. Endocrinol. 12, 691557 (2021).","journal-title":"Front. Endocrinol."},{"key":"283_CR49","doi-asserted-by":"publisher","first-page":"eaba8415","DOI":"10.1126\/sciadv.aba8415","volume":"6","author":"AR Wasylishen","year":"2020","unstructured":"Wasylishen, A. R. et al. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Sci. Adv. 6, eaba8415 (2020).","journal-title":"Sci. Adv."},{"key":"283_CR50","doi-asserted-by":"publisher","first-page":"dmm049552","DOI":"10.1242\/dmm.049552","volume":"15","author":"C Sun","year":"2022","unstructured":"Sun, C. et al. Context matters\u2013Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas. Dis. Models Mech. 15, dmm049552 (2022).","journal-title":"Dis. Models Mech."},{"key":"283_CR51","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng, W. M. et al. Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut 71, 961\u2013973 (2022).","journal-title":"Gut"},{"key":"283_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","volume":"36","author":"S Yachida","year":"2012","unstructured":"Yachida, S. et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am. J. Surg. Pathol. 36, 173\u2013184 (2012).","journal-title":"Am. J. Surg. Pathol."},{"key":"283_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/MPA.0b013e31826cb243","volume":"42","author":"JA Gilbert","year":"2013","unstructured":"Gilbert, J. A. et al. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas 42, 411\u2013421 (2013).","journal-title":"Pancreas"},{"key":"283_CR54","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","volume":"15","author":"HA Lane","year":"2009","unstructured":"Lane, H. A. et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res. 15, 1612\u20131622 (2009).","journal-title":"Clin. Cancer Res."},{"key":"283_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","volume":"319","author":"YY Zaytseva","year":"2012","unstructured":"Zaytseva, Y. Y., Valentino, J. D., Gulhati, P. & Evers, B. M. mTOR inhibitors in cancer therapy. Cancer Lett. 319, 1\u20137 (2012).","journal-title":"Cancer Lett."},{"key":"283_CR56","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1038\/onc.2014.164","volume":"34","author":"KM Dodd","year":"2015","unstructured":"Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R. & Tee, A. R. mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34, 2239\u20132250 (2015).","journal-title":"Oncogene"},{"key":"283_CR57","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.3390\/ijms22084041","volume":"22","author":"F Marini","year":"2021","unstructured":"Marini, F., Giusti, F., Tonelli, F. & Brandi, M. L. Pancreatic neuroendocrine neoplasms in multiple endocrine neoplasia type 1. Int. J. Mol. Sci. 22, 4041 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"283_CR58","doi-asserted-by":"publisher","first-page":"645","DOI":"10.21037\/jgo.2019.01.33","volume":"10","author":"JE Nu\u00f1ez","year":"2019","unstructured":"Nu\u00f1ez, J. E. et al. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J. Gastrointest. Oncol. 10, 645 (2019).","journal-title":"J. Gastrointest. Oncol."},{"key":"283_CR59","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/157015912804499537","volume":"10","author":"P Curatolo","year":"2012","unstructured":"Curatolo, P. & Moavero, R. mTOR inhibitors in tuberous sclerosis complex. Curr. Neuropharmacol. 10, 404\u2013415 (2012).","journal-title":"Curr. Neuropharmacol."},{"key":"283_CR60","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/bioinformatics\/btw661","volume":"33","author":"J Schwab","year":"2017","unstructured":"Schwab, J., Burkovski, A., Siegle, L., M\u00fcssel, C. & Kestler, H. A. ViSiBooL-visualization and simulation of Boolean networks with temporal constraints. Bioinformatics 33, 601\u2013604 (2017).","journal-title":"Bioinformatics"},{"key":"283_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06498-2","volume":"9","author":"CS Chan","year":"2018","unstructured":"Chan, C. S. et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat. Commun. 9, 4158 (2018).","journal-title":"Nat. Commun."},{"key":"283_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","volume":"28","author":"E Missiaglia","year":"2010","unstructured":"Missiaglia, E. et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28, 245\u2013255 (2010).","journal-title":"J. Clin. Oncol."},{"key":"283_CR63","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1093\/bioinformatics\/18.suppl_1.S96","volume":"18","author":"W Huber","year":"2002","unstructured":"Huber, W., von Heydebreck, A., S\u00fcltmann, H., Poustka, A. & Vingron, M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18, S96\u2013S104 (2002).","journal-title":"Bioinformatics"},{"key":"283_CR64","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s11063-017-9706-3","volume":"48","author":"L Lausser","year":"2018","unstructured":"Lausser, L., Szekely, R., Schirra, L.-R. & Kestler, H. A. The influence of multi-class feature selection on the prediction of diagnostic phenotypes. Neural Process. Lett. 48, 863\u2013880 (2018).","journal-title":"Neural Process. Lett."},{"key":"283_CR65","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/106652700750050943","volume":"7","author":"A Ben-Dor","year":"2000","unstructured":"Ben-Dor, A. et al. Tissue classification with gene expression profiles. J. Comput Biol. 7, 559\u2013583 (2000).","journal-title":"J. Comput Biol."},{"key":"283_CR66","unstructured":"Lausser, L., Sch\u00e4fer, L. M., Szekely, R. & Kestler, H. A. ORION: Ordinal Relations in R. R package version 1.0.3, https:\/\/CRAN.R-project.org\/package=ORION (2022)."},{"key":"283_CR67","doi-asserted-by":"crossref","unstructured":"Lausser, L., Szekely, R., Kessler, V., Schwenker, F. & Kestler, H. A. Selecting features from foreign classes. Artificial Neural Networks in Pattern Recognition: 8th IAPR TC3 Workshop, ANNPR 2018, Siena, Italy, September 19\u201321, 2018, Proceedings, LNAI 11081, 66\u201377 (Springer, 2018).","DOI":"10.1007\/978-3-319-99978-4_5"},{"key":"283_CR68","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/bioinformatics\/btq124","volume":"26","author":"C M\u00fcssel","year":"2010","unstructured":"M\u00fcssel, C., Hopfensitz, M. & Kestler, H. A. BoolNet-an R package for generation, reconstruction and analysis of Boolean networks. Bioinformatics 26, 1378\u20131380 (2010).","journal-title":"Bioinformatics"},{"key":"283_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-0716-2277-3_12","volume":"2488","author":"N Ikonomi","year":"2022","unstructured":"Ikonomi, N., Werle, S. D., Schwab, J. D. & Kestler, H. A. Discrete logic modeling of cell signaling pathways. Methods Mol. Biol. 2488, 159\u2013181 (2022).","journal-title":"Methods Mol. Biol."},{"key":"283_CR70","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nature13255","volume":"510","author":"JT Rodgers","year":"2014","unstructured":"Rodgers, J. T. et al. mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). Nature 510, 393\u2013396 (2014).","journal-title":"Nature"},{"key":"283_CR71","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1002\/stem.2056","volume":"33","author":"M Rumman","year":"2015","unstructured":"Rumman, M., Dhawan, J. & Kassem, M. Concise review: quiescence in adult stem cells: biological significance and relevance to tissue regeneration. Stem Cells 33, 2903\u20132912 (2015).","journal-title":"Stem Cells"},{"key":"283_CR72","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2174\/138920209789208237","volume":"10","author":"Y Xiao","year":"2009","unstructured":"Xiao, Y. A tutorial on analysis and simulation of boolean gene regulatory network models. Curr. Genomics 10, 511\u2013525 (2009).","journal-title":"Curr. Genomics"},{"key":"283_CR73","doi-asserted-by":"publisher","first-page":"8710","DOI":"10.1073\/pnas.1536783100","volume":"100","author":"M Aldana","year":"2003","unstructured":"Aldana, M. & Cluzel, P. A natural class of robust networks. Proc. Natl Acad. Sci. USA 100, 8710\u20138714 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"283_CR74","doi-asserted-by":"crossref","unstructured":"Gillespie, C. S. Fitting heavy tailed distributions: the poweRlaw package. Preprint at https:\/\/arxiv.org\/abs\/1407.3492 (2014).","DOI":"10.18637\/jss.v064.i02"},{"key":"283_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12, 77 (2011).","journal-title":"BMC Bioinform."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-023-00283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-023-00283-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-023-00283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T14:06:46Z","timestamp":1685801206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-023-00283-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1038\/s41540-023-00283-8","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}